Skip to main content

Pemetrexed (LY-231514)

$109.00
SKU:
C5923-10
Adding to cart… The item has been added

Pemetrexed (LY-231514) is an antifolate that inhibits thymidylate synthase (TS) (Ki = 1.3 nM) and multiple folate-requiring enzymes, such as dihydrofolate reductase (DHFR) (Ki = 7.2 nM) and glycinamide ribonucleotide formyltransferase (GARFT) (Ki = 65 nM). [1]
Pemetrexed (LY-231514) has been studied as a potential treatment option in multiple tumor types, and has been approved in 2004 for the treatment of pleural mesothelioma [2] and non-small cell lung cancer (NSCLC) [3].
A recent clinical study reveals that platinum combination with Pemetrexed (LY-231514) significantly improved the disease control rate and resulted in a tendency toward prolongation of progression-free survival in NSCLC patients who progressed after first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). [4]"


Technical information:

Chemical Formula:   C20H19N5Na2O6
CAS #:   150399-23-8
Molecular Weight:   471.37
Purity:   > 98%
Appearance:   White
Chemical Name:   sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
Solubility:   Up to 100 mM in DMSO
Synonyms:   Pemetrexed, LY-231514, LY231514

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.


Reference:

1. Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997. 57(6):1116-23. Pubmed ID: 9067281
2. Hazarika M, et al. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004. 9(5):482-8. Pubmed ID: 15477632
3. Cohen MH, et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist. 2005. 10(6):363-8. Pubmed ID: 15967829
4. Lee SJ, et al. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung Cancer. 2015. 90(2):261-6. Pubmed ID: 15477632

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.